دورية أكاديمية
Cardiovascular Safety of Metoclopramide Compared to Domperidone: A Population-Based Cohort Study.
| العنوان: | Cardiovascular Safety of Metoclopramide Compared to Domperidone: A Population-Based Cohort Study. |
|---|---|
| المؤلفون: | Cowan A; Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada., Garg AX; Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.; ICES, London, Ontario, Canada., McArthur E; ICES, London, Ontario, Canada., Muanda Tsobo F; ICES, London, Ontario, Canada., Weir MA; Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.; ICES, London, Ontario, Canada. |
| المصدر: | Journal of the Canadian Association of Gastroenterology [J Can Assoc Gastroenterol] 2020 Dec 18; Vol. 4 (5), pp. e110-e119. Date of Electronic Publication: 2020 Dec 18 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101738684 Publication Model: eCollection Cited Medium: Internet ISSN: 2515-2092 (Electronic) Linking ISSN: 25152084 NLM ISO Abbreviation: J Can Assoc Gastroenterol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Oxford] : Oxford University Press, [2018]- |
| مستخلص: | Background: Metoclopramide and domperidone are common prokinetics used to alleviate gastrointestinal symptoms. However, both drugs may trigger ventricular arrhythmias. Aim: We conducted this population-based study to compare the 30-day cardiovascular safety of metoclopramide versus domperidone in outpatient care. Methods: We used health care databases to identify a cohort of patients in Ontario, Canada newly dispensed metoclopramide or domperidone. Inverse probability of treatment weighting based on propensity scores was used to balance the baseline characteristics of the two groups. All outcomes were assessed in the 30 days following drug dispensing. The primary outcome was hospital encounter with ventricular arrhythmia. The secondary outcomes were hospital encounter with cardiac arrest, all-cause mortality and cardiovascular mortality. Results: We identified 196,544 patients, 19% of whom were prescribed metoclopramide. There was no difference in the risk of a hospital encounter with ventricular arrythmia (0.02% in both groups), or cardiac arrest (0.10% with metoclopramide and 0.08% with domperidone). However, 1.34% of patients died after starting metoclopramide compared to 0.52% of patients starting domperidone; weighted risk ratio 2.50 (95% confidence interval [CI] 2.13 to 3.03). Similarly, 0.42% of patients died of cardiovascular causes after starting metoclopramide compared to 0.19 % of patients starting domperidone; weighted risk ratio 2.00 (95% CI 1.44 to 2.77). Conclusion: The 30-day risk for a hospital encounter with ventricular arrhythmia was low for both metoclopramide and domperidone, with no significant difference in the rate between the two drugs. The higher 30-day risk of death observed with metoclopramide compared with domperidone in this study has also been observed in other studies and warrants further investigation. (© The Author(s) 2020. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.) |
| References: | J Am Coll Cardiol. 1996 May;27(6):1335-42. (PMID: 8626941) Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38. (PMID: 23147521) Pharmacology. 2005 Apr;74(1):31-6. (PMID: 15640612) J Clin Epidemiol. 2005 Dec;58(12):1325-9. (PMID: 16291479) Health Serv Res. 2008 Aug;43(4):1424-41. (PMID: 18756617) CMAJ. 2016 Apr 19;188(7):E120-E129. (PMID: 26903359) Ann Intern Med. 2009 Apr 7;150(7):502-4. (PMID: 19349637) Resuscitation. 2016 Jan;98:9-14. (PMID: 26476197) J Cardiovasc Pharmacol. 2005 Mar;45(3):197-203. (PMID: 15725943) Br J Clin Pharmacol. 2018 Nov;84(11):2551-2561. (PMID: 29975795) Circulation. 2014 Nov 18;130(21):1883-90. (PMID: 25399397) United European Gastroenterol J. 2018 Nov;6(9):1331-1346. (PMID: 30386606) Clin Pract. 2011 Nov 02;1(4):e83. (PMID: 24765383) Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:148-53. (PMID: 22262601) Aliment Pharmacol Ther. 2003 Jul 1;18(1):151-5. (PMID: 12848637) Clin Drug Investig. 2016 Feb;36(2):97-107. (PMID: 26649742) Multivariate Behav Res. 2011 May;46(3):399-424. (PMID: 21818162) Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):881-8. (PMID: 20652862) Drug Saf. 2015 Dec;38(12):1187-99. (PMID: 26350642) Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):555-62. (PMID: 19844945) BMJ. 2018 Nov 14;363:k3532. (PMID: 30429167) Drugs Aging. 2014 Nov;31(11):805-13. (PMID: 25227452) Europace. 2014 Jan;16(1):101-8. (PMID: 23833046) Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):841-8. (PMID: 26098410) PLoS One. 2013 Aug 28;8(8):e72148. (PMID: 24015213) Ther Adv Cardiovasc Dis. 2018 Feb;12(2):39-51. (PMID: 29224509) Can J Kidney Health Dis. 2020 Feb 05;7:2054358119887988. (PMID: 32076569) |
| فهرسة مساهمة: | Keywords: Cardiovascular death; Gastroparesis; Prokinetic |
| تواريخ الأحداث: | Date Created: 20211007 Latest Revision: 20231107 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8489520 |
| DOI: | 10.1093/jcag/gwaa041 |
| PMID: | 34617008 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2515-2092 |
|---|---|
| DOI: | 10.1093/jcag/gwaa041 |